Company Overview
Beijing
Guangzhou
EdiGene is a clinical-stage biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer.
-
2015
Founded
-
3
Locations
-
4
R&D platforms
-
120+
employees
Global Layout
Our History
May 2015
Company founded
June 2016
First gene editing cell lines developed
April 2017
First platform for gene editing therapy established
November 2017
First collaboration with clinicians
May 2018
First collaboration with MNC pharmaceutical company
November 2018
Gene editing clinical application base compatible with GMP established
January 2019
Clinical-scale manufacturing capability built-up
February 2019
Clinical department established
July 2019
KO cell lines acquired by Abcam
December 2019
Poster presentation of ET-01 data at ASH
May 2020
Oral presentation of RNA base editing program data at ASGCT annual meeting
May 2020
Collaboration with Immunochina to jointly develop allogeneic CAR-T Therapy for Cancer
October 2020
EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration
January 2021
EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration
